Patents by Inventor Eva Maria Martin De La Nava

Eva Maria Martin De La Nava has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oxazolo[5-4-b]pyridin-5-yl compounds
    Patent number: 8288548
    Abstract: The present invention provides oxazolo[5,4-b]pyridin-5-yl compounds useful in the treatment of cancer.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: October 16, 2012
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Raymond Gilmour, Jose Alfredo Martin, Eva Maria Martin de la Nava
  • OXAZOLO[5-4-b]PYRIDIN-5-YL COMPOUNDS
    Publication number: 20120142724
    Abstract: The present invention provides oxazolo[5,4-b]pyridin-5-yl compounds useful in the treatment of cancer.
    Type: Application
    Filed: November 17, 2011
    Publication date: June 7, 2012
    Applicant: Eli Lilly and Company
    Inventors: David Andrew Coates, Raymond Gilmour, Jose Alfredo Martin, Eva Maria Martin de la Nava
  • Protein kinase inhibitors
    Patent number: 7855211
    Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: December 21, 2010
    Assignee: Eli Lilly and Company
    Inventors: David A Coates, Lawrence Mark Gelbert, John M. Knobeloch, Alfonso De Dios Magana, Ana De Prado Gonzalez, Miriam Filadelfa Del Prado Catalina, Maria Cristina Garcia Paredes, Eva Maria Martin De La Nava, Maria Dolores Martin Ortega Finger, Jose Antonio Martinez Perez, Ana Isabel Mateo Herranz, Carlos Perez Martinez, Concepcion Sanchez Martinez
  • Compounds and Methods for Treating Dyslipidemia
    Publication number: 20100204207
    Abstract: Compounds of Formula (I): wherein n, m, p, q, Y, R1, R2, R3a, R3b, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed.
    Type: Application
    Filed: April 20, 2010
    Publication date: August 12, 2010
    Inventors: Xinchao Chen, Christopher Lawrence Cioffi, Sean Richard Dinn, Ana Maria Escribano, Maria Carmen Fernandez, Todd Fields, Robert Jason Herr, Nathan Bryan Mantlo, Eva Maria Martin De La Nava, Ana Isabel Mateo Herranz, Saravanan Parthasarathy, Xiaodong Wang
  • Compounds and methods for treating dislipidemia
    Patent number: 7749992
    Abstract: Compounds of formula I wherein n, m, p, q, y, R1 R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating artherosclerosis and its sequelae.
    Type: Grant
    Filed: October 7, 2004
    Date of Patent: July 6, 2010
    Assignee: Eli Lilly and Company
    Inventors: Guoqing Cao, Ana Maria Escribano, Maria Carmen Fernandez, Todd Fields, Douglas Linn Gernert, Christopher Lawrence Cioffi, Robert Jason Herr, Nathan Bryan Mantlo, Eva Maria Martin De La Nava, Ana Isabel Mateo Herranz, Daniel Ray Mayhugh, Xiaodong Wang
  • PROTEIN KINASE INHIBITORS
    Publication number: 20100160340
    Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases.
    Type: Application
    Filed: December 15, 2009
    Publication date: June 24, 2010
    Inventors: David A. COATES, Lawrence Mark GELBERT, John M. KNOBELOCH, Alfonso DE DIOS MAGANA, Ana DE PRADO GONZALEZ, Miriam FILADELFA DEL PRADO CATALINA, Maria Cristina GARCIA PAREDES, Eva Maria MARTIN DE LA NAVA, Maria Dolores MARTIN ORTEGA FINGER, Jose Antonio MARTINEZ PEREZ, Ana Isabel MATEO HERRANZ, Carlos PEREZ MARTINEZ, Concepcion SANCHEZ MARTINEZ
  • Compounds and methods for treating dyslipidemia
    Patent number: 7470705
    Abstract: The present invention discloses compounds of formula (I) wherein A, n, q, K, W, X, Y; Z, R1, R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and its sequelae.
    Type: Grant
    Filed: March 17, 2005
    Date of Patent: December 30, 2008
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Guoqing Cao, Ana Maria Escribano, Maria Carmen Fernandez, Peter Ambrose Lander, Nathan Bryan Mantlo, Eva Maria Martin de la Nava, Ana Isabel Mateo Herranz, Daniel Ray Mayhugh, Xiaodong Wang
  • Compounds and Methods for Treating Dyslipidemia
    Publication number: 20080269284
    Abstract: Compounds of Formula I wherein n, q, Y, R1, R2a, R2b, R3a, R3b, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed.
    Type: Application
    Filed: June 22, 2005
    Publication date: October 30, 2008
    Applicant: ELI LILLY AND COMPANY
    Inventors: Ana Maria Escribano, Maria Carmen Fernandez, Nathan Bryan Mantlo, Ana Isabel Mateo-Herranz, Eva Maria Martin De La Nava, Xiaodong Wang
  • Growth hormone secretagogues
    Patent number: 7396846
    Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.
    Type: Grant
    Filed: March 31, 2003
    Date of Patent: July 8, 2008
    Assignee: Eli Lilly and Company
    Inventors: Britta Evers, Ruehter Gerd, Eva Maria Martin De La Nava, Mark Joseph Tebbe